Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aripiprazole

FDA-approved product (tablet, oral), marketed as Abilify, Abilify Asimtufii, Abilify Maintena Kit and 4 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aripiprazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aggressive behavior
  • Agitation
  • Autism
  • Bipolar disorder
  • Bipolar I disorder
  • Depressive disorder
  • Major depressive disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aripiprazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aripiprazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole

    NCT01155544 · start 2011-06

    Registered record
    Registry ID
    NCT01155544
    Conditions
    Substance Abuse; Substance Dependence
    Interventions
    Behavioral Intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2011-06
    Completion
    2014-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSubstance Abuse; Substance Dependence
    InterventionBehavioral Intervention
    PhasePhase 4
    Registry statusWithdrawn

  • Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder

    NCT01227668 · start 2011-03

    Registered record
    Registry ID
    NCT01227668
    Conditions
    Irritability Associated With Autistic Disorder
    Interventions
    Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2012-06
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritability Associated With Autistic Disorder
    InterventionAripiprazole; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

    NCT01111552 · start 2010-07-29

    Registered record
    Registry ID
    NCT01111552
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    Escitalopram; Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-07-29
    Completion
    2011-09-27
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionEscitalopram; Aripiprazole; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Safety and Efficacy of Cariprazine in Patients With Schizophrenia

    NCT01104766 · start 2010-04-23

    Registered record
    Registry ID
    NCT01104766
    Conditions
    Schizophrenia
    Interventions
    Cariprazine; Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-04-23
    Completion
    2011-12-20
    Enrolment
    617

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionCariprazine; Aripiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders

    NCT01028820 · start 2009-08

    Registered record
    Registry ID
    NCT01028820
    Conditions
    Autism Spectrum Disorder
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-08
    Completion
    2011-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutism Spectrum Disorder
    InterventionAripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Juvenile Bipolar Disorder Outpatient Program

    NCT01000402 · start 2008-02

    Registered record
    Registry ID
    NCT01000402
    Conditions
    Bipolar Disorder; Attention Deficit Disorder With Hyperactivity
    Interventions
    Psychopharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2014-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Attention Deficit Disorder With Hyperactivity
    InterventionPsychopharmacotherapy
    PhasePhase 4
    Registry statusUnknown

  • A Multicenter Investigative Study of the Safety and Efficacy of Long-term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode

    NCT00606229 · start 2008-01

    Registered record
    Registry ID
    NCT00606229
    Conditions
    Bipolar I Disorder
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-01
    Completion
    2010-11
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionAripiprazole
    PhasePhase 3
    Registry statusCompleted

  • Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

    NCT00545675 · start 2007-12

    Registered record
    Registry ID
    NCT00545675
    Conditions
    Bipolar Disorder
    Interventions
    Abilify(aripiprazole); Depakote (divalproate)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2010-07
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAbilify(aripiprazole); Depakote (divalproate)
    PhasePhase 4
    Registry statusCompleted

  • Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia

    NCT00395915 · start 2006-09

    Registered record
    Registry ID
    NCT00395915
    Conditions
    Schizophrenia
    Interventions
    aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2006-09
    Completion
    2009-12
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionaripiprazole
    PhasePhase 4
    Registry statusUnknown

  • Aripiprazole and Effexor XR Drug Interaction Study

    NCT00362271 · start 2006-08

    Registered record
    Registry ID
    NCT00362271
    Conditions
    Healthy
    Interventions
    Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-09
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionVenlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
    PhasePhase 1
    Registry statusCompleted

  • Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder

    NCT00241176 · start 2005-09

    Registered record
    Registry ID
    NCT00241176
    Conditions
    Tourette's Syndrome; Tic Disorders
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-09
    Completion
    2010-02
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette's Syndrome; Tic Disorders
    InterventionAripiprazole
    PhasePhase 4
    Registry statusCompleted

  • A Switch Study of BMS-337039 in Schizophrenic Out-patients

    NCT00232687 · start 2005-06-01

    Registered record
    Registry ID
    NCT00232687
    Conditions
    Schizophrenia
    Interventions
    Aripiprazole; Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-06-01
    Completion
    2007-04-01
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionAripiprazole; Aripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)

    NCT00116259 · start 2005-03

    Registered record
    Registry ID
    NCT00116259
    Conditions
    Bipolar Disorder; Attention Deficit Hyperactivity Disorder
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-03
    Completion
    2008-02
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Attention Deficit Hyperactivity Disorder
    InterventionAripiprazole
    PhaseNot applicable
    Registry statusCompleted

  • Abilify Therapy for Reducing Comorbid Substance Abuse

    NCT00208169 · start 2005-03

    Registered record
    Registry ID
    NCT00208169
    Conditions
    Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Anxiety Disorders; Substance Abuse
    Interventions
    Aripiprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-03
    Completion
    2007-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder +2 more
    InterventionAripiprazole
    PhasePhase 4
    Registry statusCompleted

  • Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

    NCT00194012 · start 2004-08

    Registered record
    Registry ID
    NCT00194012
    Conditions
    Bipolar Disorder
    Interventions
    Aripiprazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-08
    Completion
    2012-06
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionAripiprazole; Placebo
    PhasePhase 3
    Registry statusCompleted